Voyager Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Samantha Semenkow from Citi reiterated a Buy rating on the stock and has a $11.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Samantha Semenkow has given his Buy rating due to a combination of factors reflecting both the opportunity and the valuation embedded in Voyager Therapeutics. While recent Alzheimer’s tau antibody readouts from larger peers showed mixed clinical outcomes, they still demonstrated that targeted biologics can meaningfully reduce pathological tau accumulation, keeping the mechanistic rationale for Voyager’s anti‑tau program intact.
In this context, the neutral readthrough from posdinemab and bepranemab to Voyager’s c‑terminal–targeting VY7523 leaves room for differentiated biology and potential benefit on tau spread that has yet to be tested in humans, with key tau‑PET data expected in 2H26. Coupled with a High Risk designation and an implied upside of roughly 185% to the analyst’s target, Semenkow views the current share price as overly discounting clinical and platform optionality, justifying a Buy recommendation despite the inherent early‑stage development risk.
In another report released on March 17, H.C. Wainwright also reiterated a Buy rating on the stock with a $25.00 price target.
Based on the recent corporate insider activity of 19 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VYGR in relation to earlier this year.